VEGFA and COVID-19: Although evidence in favor of this is still scarce, the levels of circulating VEGF-A may be elevated in long COVID-19 patients and vaccinated individuals suffering from certain side effects, suggesting that VEGF-A could be one of the possible biomarkers for monitoring such neurovascular defects [105,106,117].